Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2021 December;63(4) > Panminerva Medica 2021 December;63(4):472-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Panminerva Medica 2021 December;63(4):472-7

DOI: 10.23736/S0031-0808.20.03961-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Primary benign back pain: supplementation with Pycnogenol®

David COX 1, Gianni BELCARO 1, 2, 3 , Maria R. CESARONE 1, 2, 3, Roberto COTELLESE 1, Mark DUGALL 1, 2, 3, Beatrice FERAGALLI 2, Morio HOSOI 1, Marcello CORSI 1, Roberta LUZZI 1

1 IRVINE3 Vascular/Circulation Labs, Pescara, Italy; 2 Radiology, Department of Medical, Oral and Biotechnological Sciences, D’Annunzio University, Pescara, Italy; 3 IAAPS, International Agency for Pharma Standard Supplements, Pescara, Italy



BACKGROUND: Back pain (BP) is one of the most common problems seen by general practitioners. The aim of this pilot registry study was to evaluate the effects of Pycnogenol® (French Maritime Pine Bark extract) on pain, mobility and muscle spasm in patients with recurring episodes of back pain without any other clinical condition.
METHODS: The registry follow-up lasted 3 weeks. Subjects used either SM (standard management), including mild exercise and 3 days of resting or immobilization - or SM+Pycnogenol® 200 mg/day (4 cps/day).
RESULTS: Eighty-two subjects were included in the study, 23 took Pycnogenol® and 59 were in the SM group. No safety problems or tolerability problems were observed with Pycnogenol® or with the SM. The two groups, SM and SM+Pycnogenol®, were comparable at inclusion. A prevalent localization to the lower part of the back/spine was observed in all patients of both groups. The improvement in Karnofsky performance status Scale - expressing the global physical capacity of the individuals - during the 3 weeks of follow-up was significantly higher and faster in the Pycnogenol® group (P<0.05) compared to SM. Patients were able to restart physical training in 3 weeks with Pycnogenol® (in comparison with 4.5 weeks with SM only). The decrease in back pain score (VASL score) was faster and more pronounced with Pycnogenol® (P<0.05) compared to SM. Oxidative stress was significantly reduced in subjects using Pycnogenol® (P<0.05) while it remained elevated in the control group. The use of the rescue medication doses (ibuprofen) was significantly higher in the SM only (P<0.05) in comparison with SM+Pycnogenol®.
CONCLUSIONS: Pycnogenol® appears to be an effective and safe supplementary management in healthy subjects with idiopathic BP. Mobility, pain, general physical capacity and oxidative stress improved in only a week with further improvements up to 4 weeks in most patients; results appear to be better and faster with Pycnogenol® supplementation than with SM alone.


KEY WORDS: Back pain; Pycnogenols; Dietary supplements; Pain

inizio pagina